Nail biting wait with SUVN 502 data announcement Suven reported a strong performance during Q4FY19. Revenue grew 19% YoY, due to a 64% YoY rise in specialty chemicals. Core CRAMS grew 4% to ` 718mn, whereas commercial CRAMS fell 23% YoY to ` 420mn (` 800mn for FY19). CTS grew 26% YoY, including Taro royalty worth ` 24mn. The management expects commercial revenue to be in the range of ` 1.3mn in FY20 and flat specialty chemicals. SUVN 502 could be a positive trigger, if the data is favourable. Based on a conservative approach, we estimate a...